Interpace Diagnostics (IDXG) Misses Q1 EPS by 4c, Revenues Miss; Offers FY19 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
May 13, 2019 4:05 PM EDTQuarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year
Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase
Conference Call and Webcast Monday May 13, 2019 at 4:30 pm ET
Parsippany, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced financial results for the first quarter ended March 31, 2019, and reviewed recent business progress.
We had a strong start to the year highlighted by growth and driven by increasing volume in our... More
